Monitor FDA's decision on the jurisdiction request and any subsequent guidance on trial design. The withdrawal of the SPA removes a key regulatory milestone, and the program's viability depends on whether the new division agrees on a feasible development path. Watch for potential impact on reproxalap program and cash runway updates.
Drug in focus
ALDX drug pipeline →ADX-2191
▼ Bearish Named in this 8-K- Impact
- Phase
- Phase 2 (RP completed); Phase 3 (PVRL on hold)
- Time to market
- Uncertain. The PVRL program is in regulatory limbo after the SPA withdrawal and IND transfer request. The RP program has Fast Track designation but no Phase 2/3 trial has been confirmed as initiated. Even under optimistic scenarios, any potential approval is likely several years away.
- Next catalyst
- None dated
What to watchWatch for the FDA's decision on Aldeyra's jurisdiction transfer request for ADX-2191's IND, which will determine which division oversees the PVRL program and what development path will be required. Also monitor whether the planned Phase 2/3 trial in retinitis pigmentosa ever initiates, as that would provide a future catalyst. The company's cash runway and the reproxalap appeal outcome are broader factors affecting ALDX's ability to fund ADX-2191 development.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 10 $0.6291entry
- T+1 · 6d ago +3.54%α +2.23% · $0.6514
- T+5 · 10h ago +10.30%α +12.63% · $0.6939
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Aldeyra Therapeutics requested FDA transfer of its ADX-2191 IND for primary vitreoretinal lymphoma from the Division of Ophthalmology to the Division of Hematologic Malignancies 2, and withdrew its Special Protocol Assessment agreement. The regulatory path is now uncertain, the planned clinical trial is on hold, and the program faces potential delays, redesign, or discontinuation.
Key Facts
- Aldeyra requested FDA transfer of ADX-2191 IND from Division of Ophthalmology to Division of Hematologic Malignancies 2
- Aldeyra withdrew the Special Protocol Assessment (SPA) protocol for ADX-2191 in PVRL
- Company does not expect to initiate the SPA-contemplated clinical trial while jurisdictional request is pending
- ADX-2191 previously received a Complete Response Letter in June 2023 for lack of substantial evidence of effectiveness
- Any redesigned trial may be larger, longer, more costly, and harder to enroll given PVRL rarity
- Outcome could delay or prevent NDA resubmission, increase costs, shorten cash runway, and require additional capital
- Actions could adversely affect FDA interactions on other programs including reproxalap
Financial Impact
No specific financial figures provided; company warns of increased costs, shortened cash runway, and need for additional capital
Risk Factors
- FDA may deny the transfer request or assign to a division other than DHM2
- If IND remains with DO, withdrawal of SPA could adversely affect DO's review
- New division may require different or additional trials, data, or analyses
- Program may be deemed not feasible, similar to prior discontinuation in proliferative vitreoretinopathy
- Orphan drug exclusivity may be lost if another methotrexate product gains approval first
- Regulatory uncertainty could affect other Aldeyra programs including reproxalap
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-453537 |
| Document: 0001193125-26-453537-index-headers.html | 0001193125-26-453537 |
| Document: 0001193125-26-453537-index.html | 0001193125-26-453537 |
| Document: 0001193125-26-453537.txt | 0001193125-26-453537 |
Track record
12 reports on ALDX
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +59.67% at T+60 after the Aug 16, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 17, 2026today 8-K Bearish 7/10 Entry $0.6799 Now $0.6939 −2.06% settles Dec 17
- Nov 13, 20264d ago Insider Cluster Neutral 4/10 Entry $0.6696 Now $0.6939 +3.63% settles Dec 15
- Nov 12, 20265d ago SC 13G/A Bearish 5/10 Entry $0.6301 Now $0.6939 −10.13% settles Dec 11
- Nov 9, 20268d ago 8-K Bearish 6/10 Viewing Entry $0.6291 Now $0.6939 −10.30% settles Dec 9
- Nov 6, 202611d ago SC 13G Neutral 3/10 Entry $0.6337 Now $0.6939 +9.50% settles Dec 7
- Nov 4, 202613d ago Institutional Cluster Bearish 4/10 Entry $0.6474 Now $0.6939 −7.18% settles Dec 3
- Sep 29, 20267w ago 8-K Bullish 7/10 Entry $1.32 to $0.6412 Now $0.6939 −47.43% ▼ −51.42% −52.14% vs SPY
- Aug 16, 202613w ago Institutional Cluster Bearish 6/10 Entry $1.56 to $1.37 Now $0.6939 +55.52% ▲ +12.18% +10.20% vs SPY
- Jul 30, 202615w ago 8-K Neutral 2/10 Entry $1.54 to $1.49 Now $0.6939 −54.94% ▼ −3.57% −6.56% vs SPY
- Apr 27, 202629w ago DEFA14A Neutral 2/10 Entry $1.57 to $1.78 Now $0.6939 −55.80% ▲ +13.38% +7.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers